These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 31964195)

  • 1. The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer.
    Mather RL; Andrews H; Pandha H; Jachetti E; Micallef J; Wang Y; Crea F
    Future Oncol; 2020 Feb; 16(6):147-149. PubMed ID: 31964195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of: de novo neuroendocrine features in prostate cancer.
    Abdulfatah E; Fine SW; Lotan TL; Mehra R
    Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Akamatsu S; Inoue T; Ogawa O; Gleave ME
    Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraneoplastic Syndrome Secondary to Treatment Emergent Neuroendocrine Tumor in Metastatic Castration-resistant Prostate Cancer: A Unique Case.
    Murphy N; Shen J; Shih A; Liew A; Khalili H; Yaskiv O; Katona K; Lee A; Zhu XH
    Clin Genitourin Cancer; 2019 Feb; 17(1):e56-e60. PubMed ID: 30279116
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging Variants of Castration-Resistant Prostate Cancer.
    Vlachostergios PJ; Puca L; Beltran H
    Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroendocrine prostate cancer].
    Tritschler S; Erdelkamp R; Stief C; Hentrich M
    Urologe A; 2017 Nov; 56(11):1475-1484. PubMed ID: 29063171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
    Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
    Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms for castration-resistance of prostate carcinoma].
    Chen F; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1217-1221. PubMed ID: 29093256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo neuroendocrine features in prostate cancer.
    Abdulfatah E; Fine SW; Lotan TL; Mehra R
    Hum Pathol; 2022 Sep; 127():112-122. PubMed ID: 35810832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
    Zhang Y; Zheng D; Zhou T; Song H; Hulsurkar M; Su N; Liu Y; Wang Z; Shao L; Ittmann M; Gleave M; Han H; Xu F; Liao W; Wang H; Li W
    Nat Commun; 2018 Oct; 9(1):4080. PubMed ID: 30287808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
    Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
    Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navigating the evolving therapeutic landscape in advanced prostate cancer.
    Crawford ED; Petrylak D; Sartor O
    Urol Oncol; 2017 May; 35S():S1-S13. PubMed ID: 28283376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.
    Hu J; Han B; Huang J
    Arch Pathol Lab Med; 2020 Mar; 144(3):320-325. PubMed ID: 31644322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.